This month is our safety and pharmacovigilance focus, so pharmaphorum's Hannah Blake interviewed Amgen's Vice President ... up-to-date with the latest drug safety information.

Amgen, Inc. ( NASDAQ: AMGN) Oppenheimer 35th Annual Healthcare Life Sciences Conference Call February 12, 2025 11:20 AM ET Narimon Honarpour - Senior Vice President, Global Development Justin Claeys - ...

is to make our research synergistic with drug development efforts where target discovery, validation and prioritization efforts can be accelerated. We believe Amgen's focus and ability to ...

High dividend yields are not always as great as they may seem. Remember that a dividend yield is arrived at by dividing a stock's annual dividend amount by its current stock price.

However, we still see areas of weakness in the portfolio, including upcoming patent losses and a highly uncertain pipeline due to the complexities of running CNS trials. Historically, the firm ...

CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker in its quest to ...

In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against other stocks that Jim Cramer discusses that are leading the Dow higher in 2025. On Thursday ...

We recently published a list of Jim Cramer Discussed 10 Stocks Leading the Dow Higher in 2025. In this article, we are going ...

Why isn’t Amgen better known? I think it’s because people don’t know about its amazing anticancer franchise. When the company brings its weight loss drug MariTide to market, I bet that ...

We recently published a list of Jim Cramer Discussed 10 Stocks Leading the Dow Higher in 2025. In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against other ...